SCHEMBL6732192

SCHEMBL6732192

NS(=O)(=O)c1ccc(-c2ccccc2-c2ccc(O)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CA2 P00918 11/20 0.69
CA12 O43570 10/20 0.69
CA9 Q16790 10/20 0.69
CA1 P00915 8/20 0.69
PTGS2 P35354 6/20 0.68
PTGS1 P23219 5/20 0.68
CA7 P43166 1/20 0.56
DRD1 P21728 1/20 0.53
ABL1 P00519 1/20 0.52
ABCB1 P08183 1/20 0.52
BCR P11274 1/20 0.52
CA14 Q9ULX7 2/20 0.51
BRAF P15056 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27516551 0.86 CA12 (0.65) CA2CA12CA9CA1PTGS2
SCHEMBL4575215 0.86 CA2 (0.79) CA2CA12CA9CA1PTGS2
SCHEMBL30221774 0.84 CA12 (0.55) CA2CA12CA9CA1PTGS2
SCHEMBL283769 0.83 CA2 (1.00) CA2CA12CA9CA1PTGS2
SCHEMBL6732932 0.82 CA12 (0.73) CA2CA12CA9CA1PTGS2
SCHEMBL8657376 0.81 ABL1 (0.53) CA2CA12CA9CA1PTGS2
SCHEMBL6725808 0.81 CA2 (0.75) CA2CA12CA9CA1PTGS2
Hydrochloric Acid SCHEMBL29969444 0.81 CA2 (0.95) CA2CA12CA9CA1PTGS2
SCHEMBL11023570 0.81 CA2 (0.95) CA2CA12CA9CA1PTGS2
SCHEMBL6725783 0.81 PTGS2 (1.00) CA2CA12CA9CA1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040158074-A1 Substituted biphenyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2004-08-12 US disclosed
US-6677488-B2 AS AN EXAMPLE, 4-(4,5-DIFLUORO-2-(3-CHLORO-4-FLUOROPHENYL) PHENYLBENZENESULFONAMIDE; ANTIARTHRITIC AGENTS; ANTIPYRETICS; ANALGESICS; PROSTAGLANDIN INHIBITORS; SIDE EFFECT REDUCTION G.D. SEARLE & CO. 2004-01-13 US disclosed
US-20020169206-A1 Substituted biphenyl compounds for the treatment of inflammation G.D. SEARLE & CO. (US) 2002-11-14 US disclosed
EP-0794942-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2000-05-31 EP disclosed
EP-0794942-A1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-09-17 EP disclosed
WO-1996016934-A1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169206-A1 Substituted biphenyl compounds for the treatment of inflammation AHR, ARNT, GPBAR1 CA2 2743/4885CA12 3828/4885CA9 2885/4885
US-20040158074-A1 Substituted biphenyl compounds for the treatment of inflammation AHR, ARNT, GPBAR1 CA2 2743/4885CA12 3828/4885CA9 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.